Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1357-1370

  Schiffer, Charles A ^a   Mangu, Pamela B ^b   Wade, James C ^c   Camp Sorrell, Dawn ^d   Cope, Diane G ^e   El Rayes, Bassel F ^f   Gorman, Mark ^g   Ligibel, Jennifer ^h   Mansfield, Paul ⁱ   Levine, Mark ^j  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c Geisinger Institute   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Florida Cancer Specialists   (United States)

^f EMORY UNIVERSITY   (United States)

^g Patient Representative   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j HENDERSON GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CHLORHEXIDINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; RIFAMPICIN; SULFADIAZINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ANTISEPSIS; ARTICLE; CANCER PATIENT; CATHETER INFECTION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COCHRANE LIBRARY; FEMORAL ARTERY; FEMORAL VEIN; HUMAN; INTERNAL JUGULAR VEIN; LEUKEMIA; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDLINE; PATIENT CARE; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SUBCLAVIAN VEIN CATHETER; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VASCULAR PATENCY;

ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CENTRAL VENOUS CATHETERS; HUMANS; MEDICAL ONCOLOGY; META-ANALYSIS AS TOPIC; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; UNITED STATES;

EID: 84876098058     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.5733     Document Type: Article

References (144)

1. Pronovost P, Needham D, Berenholtz S, et al: An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355:2725-2732, 2006 (Pubitemid 46021509)
2. Pronovost P: Interventions to decrease catheter-related bloodstream infections in the ICU: The Keystone Intensive Care Unit Project. Am J Infect Control 36:S171.e1-S171.e5, 2008
3. Teichgräber UK, Pfitzmann R, Hofmann HA: Central venous port systems as an integral part of chemotherapy. Dtsch Arztebl Int 108:147-153, 2011; quiz, 154
4. Bouza E, Burillo A, Muñoz P: Catheter-related infections: Diagnosis and intravascular treatment. Clin Microbiol Infect 8:265-274, 2002 (Pubitemid 34993797)
5. Safdar N, Maki DG: Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: A meta-analysis of prospective, randomized trials. Clin Infect Dis 43:474-484, 2006 (Pubitemid 44157156)
6. Maki DG, Kluger DM, Crnich CJ: The risk of bloodstream infection in adults with different intravascular devices: A systematic review of 200 published prospective studies. Mayo Clin Proc 81:1159-1171, 2006 (Pubitemid 44316281)
7. Verso M, Agnelli G: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665-3675, 2003 (Pubitemid 46594061)
8. Kuter DJ: Thrombotic complications of central venous catheters in cancer patients. Oncologist 9:207-216, 2004
9. Akl EA, Kamath G, Yosuico V, et al: Thromboprophylaxis for patients with cancer and central venous catheters: A systematic review and a meta-analysis. Cancer 112:2483-2492, 2008
10. Lee AY, Levine MN, Butler G, et al: Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24:1404-1408, 2006 (Pubitemid 46622005)
11. Fätkenheuer G, Buchheidt D, Cornely OA, et al: Central venous catheter (CVC)-related infections in neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82:S149-S157, 2003 (suppl 2)
12. Debourdeau P, Farge-Bancel D, Bosquet L, et al: 2008 standards, options: Recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients [in French]. Bull Cancer 95:750-761, 2008
13. Wolf HH, Leithäuser M, Maschmeyer G, et al: Central venous catheter-related infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 87:863-876, 2008
14. O'Grady NP, Alexander M, Burns LA, et al: Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52:e162-e193, 2011
15. Makower D, Sparano JA, Wadler S, et al: A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. Cancer Invest 21:177-184, 2003 (Pubitemid 36532163)
16. Miller DL, O'Grady NP: Guidelines for the prevention of intravascular catheter-related infections: Recommendations relevant to interventional radiology. J Vasc Interv Radiol 14:S355-S358, 2003
17. Johansson E, Björkholm M, Björvell H, et al: Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia: A randomized study. Support Care Cancer 12:99-105, 2004 (Pubitemid 38222495)
18. Carlo JT, Lamont JP, McCarty TM, et al: A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports. Am J Surg 188:722-727, 2004
19. Biffi R, De Braud F, Orsi F, et al: A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92:1204-1212, 2001 (Pubitemid 32861670)
20. Warner BW, Haygood MM, Davies SL, et al: A randomized, prospective trial of standard Hickman compared with Groshong central venous catheters in pediatric oncology patients. J Am Coll Surg 183:140-144, 1996 (Pubitemid 26260146)
21. Henneberg SW, Jungersen D, Hole P: Durability of central venous catheters: A randomized trial in children with malignant diseases. Paediatr Anaesth 6:449-451, 1996 (Pubitemid 126440428)
22. Mueller BU, Skelton J, Callender DP, et al: A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 10:1943-1948, 1992 (Pubitemid 23064207)
23. Haire WD, Lieberman RP, Lund GB, et al: Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: Prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant 7:57-59, 1991
24. Kappers-Klunne MC, Degener JE, Stijnen T, et al: Complications from long-term indwelling central venous catheters in hematologic patients with special reference to infection. Cancer 64:1747-1752, 1989 (Pubitemid 19251150)
25. Carde P, Cosset-Delaigue MF, Laplanche A, et al: Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: A randomized trial in 100 patients with solid tumors. Eur J Cancer Clin Oncol 25:939-944, 1989 (Pubitemid 19148697)
26. Teichgräber UK, Streitparth F, Cho CH, et al: A comparison of clinical outcomes with regular- and low-profile totally implanted central venous port systems. Cardiovasc Intervent Radiol 32:975-979, 2009
27. Zürcher M, Tramèr MR, Walder B: Colonization and bloodstream infection with single- versus multi-lumen central venous catheters: A quantitative systematic review. Anesth Analg 99:177-182, 2004 (Pubitemid 38808187)
28. Dezfulian C, Lavelle J, Nallamothu BK, et al: Rates of infection for single-lumen versus multilumen central venous catheters: A meta-analysis. Crit Care Med 31:2385-2390, 2003 (Pubitemid 37100843)
29. Biffi R, Orsi F, Pozzi S, et al: Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: A randomized trial. Ann Oncol 20:935-940, 2009
30. Unal AE, Bayar S, Arat M, et al: Malpositioning of Hickman catheters, left versus right sided attempts. Transfus Apheresis Sci 28:9-12, 2003 (Pubitemid 36298585)
31. Timsit JF, Sebille V, Farkas JC, et al: Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: A prospective randomized multicenter study. JAMA 276:1416-1420, 1996 (Pubitemid 26365848)
32. Andrivet P, Bacquer A, Ngoc CV, et al: Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. Clin Infect Dis 18:199-206, 1994 (Pubitemid 24055259)
33. de Cicco M, Panarello G, Chiaradia V, et al: Source and route of microbial colonisation of parenteral nutrition catheters. Lancet 2:1258-1261, 1989 (Pubitemid 19284133)
34. Ruesch S, Walder B, Tramèr MR: Complications of central venous catheters: Internal jugular versus subclavian access: A systematic review. Crit Care Med 30:454-460, 2002 (Pubitemid 34158135)
35. Goetz AM, Wagener MM, Miller JM, et al: Risk of infection due to central venous catheters: Effect of site of placement and catheter type. Infect Control Hosp Epidemiol 19:842-845, 1998 (Pubitemid 128472206)
36. Mitchell MD, Agarwal R, Hecht TE, et al: Nonpharmacologic interventions for prevention of catheter-related thrombosis: A systematic review. J Crit Care [epub ahead of print on September 13, 2012]
37. Boland A, Haycox A, Bagust A, et al: A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technol Assess 7:iii, ix-x, 1-99, 2003
38. Bold RJ, Winchester DJ, Madary AR, et al: Prospective, randomized trial of Doppler-assisted subclavian vein catheterization. Arch Surg 133:1089-1093, 1998 (Pubitemid 28480474)
39. Mansfield PF, Hohn DC, Fornage BD, et al: Complications and failures of subclavian-vein catheterization. N Engl J Med 331:1735-1738, 1994
40. Chu KS, Hsu JH, Wang SS, et al: Accurate central venous port-A catheter placement: Intravenous electrocardiography and surface landmark techniques compared by using transesophageal echocardiography. Anesth Analg 98:910-914, 2004
41. Calvert N, Hind D, McWilliams RG, et al: The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: A systematic review and economic evaluation. Health Technol Assess 7:1-84, 2003
42. Keenan SP: Use of ultrasound to place central lines. J Crit Care 17:126-137, 2002
43. Randolph AG, Cook DJ, Gonzales CA, et al: Ultrasound guidance for placement of central venous catheters: A meta-analysis of the literature. Crit Care Med 24:2053-2058, 1996 (Pubitemid 26418901)
44. Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49:1-45, 2009
45. Eggimann P: Prevention of intravascular catheter infection. Curr Opin Infect Dis 20:360-369, 2007
46. Møller T, Borregaard N, Tvede M, et al: Patient education-a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: A randomized clinical trial. J Hosp Infect 61:330-341, 2005 (Pubitemid 43009078)
47. Bagnall-Reeb H: Evidence for the use of the antibiotic lock technique. J Infus Nurs 27:118-122, 2004
48. Institute for Healthcare Improvement: Prevent Central Line Infection. http://www.ihi.org/explore/CentralLineInfection/Pages/default.aspx
49. Hu KK, Lipsky BA, Veenstra DL, et al: Using maximal sterile barriers to prevent central venous catheter-related infection: A systematic evidence-based review. Am J Infect Control 32:142-146, 2004 (Pubitemid 38620835)
50. Ruschulte H, Franke M, Gastmeier P, et al: Prevention of central venous catheter related infections with chlorhexidine gluconate impregnated wound dressings: A randomized controlled trial. Ann Hematol 88:267-272, 2009
51. Mimoz O, Villeminey S, Ragot S, et al: Chlorhexidine-based antiseptic solution vs alcohol-based povidone-iodine for central venous catheter care. Arch Intern Med 167:2066-2072, 2007 (Pubitemid 350036705)
52. Chambers ST, Sanders J, Patton WN, et al: Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: Results from a prospective randomized controlled trial. J Hosp Infect 61:53-61, 2005 (Pubitemid 41070274)
53. Ho KM, Litton E: Use of chlorhexidine-impregnated dressing to prevent vascular and epidural catheter colonization and infection: A meta-analysis. J Antimicrob Chemother 58:281-287, 2006 (Pubitemid 44294936)
54. Vokurka S, Bystricka E, Visokaiova M, et al: Once- versus twice-weekly changing of central venous catheter occlusive dressing in intensive chemotherapy patients: Results of a randomized multicenter study. Med Sci Monit 15:CR107-CR110, 2009
55. Olson K, Rennie RP, Hanson J, et al: Evaluation of a no-dressing intervention for tunneled central venous catheter exit sites. J Infus Nurs 27:37-44, 2004 (Pubitemid 38112653)
56. Giles Y, Aksoy M, Tezelman S: What really affects the incidence of central venous catheter-related infections for short-term catheterization? Acta Chir Belg 102:256-258, 2002
57. Laura R, Degl'Innocenti M, Mocali M, et al: Comparison of two different time interval protocols for central venous catheter dressing in bone marrow transplant patients: Results of a randomized, multicenter study-The Italian Nurse Bone Marrow Transplant Group (GITMO). Haematologica 85:275-279, 2000
58. Brandt B, DePalma J, Irwin M, et al: Comparison of central venous catheter dressings in bone marrow transplant recipients. Oncol Nurs Forum 23:829-836, 1996
59. Engervall P, Ringertz S, Hagman E, et al: Change of central venous catheter dressings twice a week is superior to once a week in patients with haematological malignancies. J Hosp Infect 29:275-286, 1995
60. Shivnan JC, McGuire D, Freedman S, et al: A comparison of transparent adherent and dry sterile gauze dressings for long-term central catheters in patients undergoing bone marrow transplant. Oncol Nurs Forum 18:1349-1356, 1991
61. Benhamou E, Fessard E, Com-Nougué C, et al: Less frequent catheter dressing changes decrease local cutaneous toxicity of high-dose chemotherapy in children, without increasing the rate of catheter-related infections: Results of a randomised trial. Bone Marrow Transplant 29:653-658, 2002 (Pubitemid 34591307)
62. deMoissac D, Jensen L: Changing i.v. administration sets: Is 48 versus 24 hours safe for neutropenic patients with cancer? Oncol Nurs Forum 25:907-913, 1998
63. Powell C, Kudsk KA, Kulich PA, et al: Effect of frequent guidewire changes on triple-lumen catheter sepsis. JPEN J Parenter Enteral Nutr 12:462-464, 1988
64. Cook D, Randolph A, Kernerman P, et al: Central venous catheter replacement strategies: A systematic review of the literature. Crit Care Med 25:1417-1424, 1997 (Pubitemid 27347310)
65. Gillies D, O'Riordan L, Wallen M, et al: Timing of intravenous administration set changes: A systematic review. Infect Control Hosp Epidemiol 25:240-250, 2004 (Pubitemid 38339631)
66. Jaeger K, Zenz S, Jüttner B, et al: Reduction of catheter-related infections in neutropenic patients: A prospective controlled randomized trial using a chlorhexidine and silver sulfadiazine-impregnated central venous catheter. Ann Hematol 84:258-262, 2005 (Pubitemid 40425073)
67. Ostendorf T, Meinhold A, Harter C, et al: Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients-a double-blind, randomised, prospective, controlled trial. Support Care Cancer 13:993-1000, 2005 (Pubitemid 41636007)
68. Stoiser B, Kofler J, Staudinger T, et al: Contamination of central venous catheters in immunocompromised patients: A comparison between two different types of central venous catheters. J Hosp Infect 50:202-206, 2002 (Pubitemid 37554875)
69. Logghe C, Van Ossel C, D'Hoore W, et al: Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: A randomized controlled trial. J Hosp Infect 37:145-156, 1997 (Pubitemid 27472630)
70. Groeger JS, Lucas AB, Coit D, et al: A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. Ann Surg 218:206-210, 1993 (Pubitemid 23229149)
71. Veenstra DL, Saint S, Saha S, et al: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis. JAMA 281:261-267, 1999 (Pubitemid 29058116)
72. Niël-Weise BS, Stijnen T, van den Broek PJ: Anti-infective-treated central venous catheters for total parenteral nutrition or chemotherapy: A systematic review. J Hosp Infect 69:114-123, 2008
73. Hanna H, Benjamin R, Chatzinikolaou I, et al: Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: A prospective randomized clinical trial. J Clin Oncol 22:3163-3171, 2004 (Pubitemid 41103731)
74. Darouiche RO, Berger DH, Khardori N, et al: Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: A randomized controlled trial. Ann Surg 242:193-200, 2005 (Pubitemid 41033435)
75. Marin MG, Lee JC, Skurnick JH: Prevention of nosocomial bloodstream infections: Effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Crit Care Med 28:3332-3338, 2000
76. Abdelkefi A, Achour W, Ben Othman T, et al: Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. J Support Oncol 5:273-278, 2007 (Pubitemid 46995362)
77. Pronovost PJ, Goeschel CA, Colantuoni E, et al: Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: Observational study. BMJ 340:c309, 2010
78. Ranson MR, Oppenheim BA, Jackson A, et al: Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect 15:95-102, 1990
79. Lim SH, Smith MP, Salooja N, et al: A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies. J Antimicrob Chemother 28:109-116, 1991
80. Vassilomanolakis M, Plataniotis G, Koumakis G, et al: Central venous catheter-related infections after bone marrow transplantation in patients with malignancies: A prospective study with short-course vancomycin prophylaxis. Bone Marrow Transplant 15:77-80, 1995
81. Aquino VM, Sandler ES, Mustafa MM, et al: A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. J Pediatr Hematol Oncol 24:710-713, 2002 (Pubitemid 35448733)
82. Bock SN, Lee RE, Fisher B, et al: A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8:161-169, 1990 (Pubitemid 20032460)
83. Ranson MR, Oppenheim BA, Jackson A, et al: Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect 15:95-102, 1990
84. van de Wetering MD, van Woensel JB: Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database Syst Rev 1:CD003295, 2007
85. Cesaro S, Tridello G, Cavaliere M, et al: Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. J Clin Oncol 27:2059-2065, 2009
86. Randolph AG, Cook DJ, Gonzales CA, et al: Benefit of heparin in central venous and pulmonary artery catheters: A meta-analysis of randomized controlled trials. Chest 113:165-171, 1998 (Pubitemid 28044941)
87. Schallom ME, Prentice D, Sona C, et al: Heparin or 0.9% sodium chloride to maintain central venous catheter patency: A randomized trial. Crit Care Med 40:1820-1826, 2012
88. Sanders J, Pithie A, Ganly P, et al: A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 62:809-815, 2008
89. Fortún J, Grill F, Martín-Dá vila P, et al: Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 58:816-821, 2006
90. Henrickson KJ, Axtell RA, Hoover SM, et al: Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. J Clin Oncol 18:1269-1278, 2000 (Pubitemid 30159845)
91. Carratalà J, Niubó J, Fernández-Sevilla A, et al: Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 43:2200-2204, 1999 (Pubitemid 29421200)
92. Daghistani D, Horn M, Rodriguez Z, et al: Prevention of indwelling central venous catheter sepsis. Med Pediatr Oncol 26:405-408, 1996 (Pubitemid 26131899)
93. Wiernikowski JT, Elder-Thornley D, Dawson S, et al: Bacterial colonization of tunneled right atrial catheters in pediatric oncology: A comparison of sterile saline and bacteriostatic saline flush solutions. Am J Pediatr Hematol Oncol 13:137-140, 1991
94. Barriga FJ, Varas M, Potin M, et al: Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 28:196-200, 1997 (Pubitemid 27078422)
95. Schwartz C, Henrickson KJ, Roghmann K, et al: Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 8:1591-1597, 1990 (Pubitemid 20301191)
96. Rackoff WR, Weiman M, Jakobowski D, et al: A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr 127:147-151, 1995
97. van Rooden CJ, Schippers EF, Guiot HF, et al: Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: A randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol 26:428-433, 2008 (Pubitemid 351171695)
98. Kethireddy S, Safdar N: Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: A meta-analysis of prospective randomized trials. J Vasc Access 9:51-57, 2008 (Pubitemid 351618716)
99. Blot F, Schmidt E, Nitenberg G, et al: Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 36:105-109, 1998 (Pubitemid 28047442)
100. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427-431, 2011
101. Smith SR, Cheesbrough J, Spearing R, et al: Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 33:1193-1197, 1989 (Pubitemid 19191955)
102. Lazarus HM, Lowder JN, Anderson JM, et al: A prospective randomized trial of central venous catheter removal versus intravenous amphotericin B in febrile neutropenic patients. JPEN J Parenter Enteral Nutr 8:501-505, 1984 (Pubitemid 14044882)
103. Atkinson JB, Chamberlin K, Boody BA: A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. J Pediatr Surg 33:714-716, 1998 (Pubitemid 28213213)
104. La Quaglia MP, Caldwell C, Lucas A, et al: A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J Pediatr Surg 29:742- 745, 1994
105. Ghanem GA, Boktour M, Warneke C, et al: Catheter-related Staphylococcus aureus bacteremia in cancer patients: High rate of complications with therapeutic implications. Medicine (Baltimore) 86:54-60, 2007 (Pubitemid 46104920)
106. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007 (Pubitemid 350232226)
107. Glaser DW, Medeiros D, Rollins N, et al: Catheter-related thrombosis in children with cancer. J Pediatr 138:255-259, 2001 (Pubitemid 32156443)
108. Akl EA, Rohilla S, Barba M, et al: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: A systematic review. Cancer 113:1685-1694, 2008
109. Linenberger ML: Catheter-related thrombosis: Risks, diagnosis, and management. J Natl Compr Canc Netw 4:889-901, 2006
110. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial. Ann Intern Med 112:423-428, 1990 (Pubitemid 20098523)
111. Monreal M, Alastrue A, Rull M, et al: Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251-253, 1996 (Pubitemid 26081476)
112. Masci G, Magagnoli M, Zucali PA, et al: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21:736-739, 2003 (Pubitemid 46621911)
113. De Cicco M, Matovic M, Balestreri L, et al: Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: A randomized controlled study based on serial venographies. Ann Oncol 20:1936-1942, 2009
114. Young AM, Billingham LJ, Begum G, et al: Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): An open-label randomised trial. Lancet 373:567-574, 2009
115. Horne MK, McCloskey DJ, Calis K, et al: Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. Pharmacotherapy 26:1262-1267, 2006 (Pubitemid 44306886)
116. Niers TM, Di Nisio M, Klerk CP, et al: Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: A randomized, placebo-controlled study. J Thromb Haemost 5:1878-1882, 2007 (Pubitemid 47288945)
117. Karthaus M, Kretzschmar A, Kröning H, et al: Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17:289-296, 2006 (Pubitemid 43160120)
118. Ruud E, Holmstrøm H, De Lange C, et al: Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies: A randomized, controlled study. Acta Paediatr 95:1053-1059, 2006 (Pubitemid 44385108)
119. Couban S, Goodyear M, Burnell M, et al: Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063-4069, 2005 (Pubitemid 46211311)
120. Verso M, Agnelli G, Bertoglio S, et al: Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057-4062, 2005 (Pubitemid 46211310)
121. Abdelkefi A, Ben Othman T, Kammoun L, et al: Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease: A randomized controlled trial. Thromb Haemost 92:654-661, 2004 (Pubitemid 39248024)
122. Chaukiyal P, Nautiyal A, Radhakrishnan S, et al: Thromboprophylaxis in cancer patients with central venous catheters: A systematic review and meta-analysis. Thromb Haemost 99:38-43, 2008
123. Cunningham MS, White B, Hollywood D, et al: Primary thromboprophylaxis for cancer patients with central venous catheters: A reappraisal of the evidence. Br J Cancer 94:189-194, 2006 (Pubitemid 43151533)
124. Chan A, Iannucci A, Dager WE: Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients. Ann Pharmacother 41:635-641, 2007 (Pubitemid 46625486)
125. Akl EA, Karmath G, Yosuico V, et al: Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 3:CD006468, 2007
126. Rawson KM, Newburn-Cook CV: The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: A meta-analysis. Oncol Nurs Forum 34:1037-1043, 2007
127. Dentali F, Gianni M, Agnelli G, et al: Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: A meta-analysis. J Thromb Haemost 6:70-75, 2008
128. Tesselaar ME, Ouwerkerk J, Nooy MA, et al: Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253-2259, 2004 (Pubitemid 39348875)
129. Dillon PW, Jones GR, Bagnall-Reeb HA, et al: Prophylactic urokinase in the management of long-term venous access devices in children: A Children's Oncology Group study. J Clin Oncol 22:2718-2723, 2004 (Pubitemid 41103760)
130. Ray CE Jr, Shenoy SS, McCarthy PL, et al: Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vasc Interv Radiol 10:1330-1334, 1999
131. Solomon B, Moore J, Arthur C, et al: Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: A multicentre randomised comparison of urokinase versus heparin. Eur J Cancer 37:2379-2384, 2001 (Pubitemid 33097474)
132. Frank JL, Garb JL, Halla B, et al: Ionic implantation of silicone chronic venous access devices does not alter thrombotic complications: A double-blinded, randomized clinical trial. Surgery 129:547-551, 2001 (Pubitemid 32374985)
133. Harter C, Salwender HJ, Bach A, et al: Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: A prospective comparison of silver-coated and uncoated catheters. Cancer 94:245-251, 2002 (Pubitemid 34049065)
134. Deitcher SR, Fraschini G, Himmelfarb J, et al: Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients. J Vasc Interv Radiol 15:575-580, 2004
135. Haire WD, Atkinson JB, Stephens LC, et al: Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 72:543-547, 1994 (Pubitemid 24305647)
136. Horne MK 3rd, Mayo DJ: Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol 15:2709-2714, 1997
137. Gabrail N, Sandler E, Charu V, et al: TROPICS 1: A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters. J Vasc Interv Radiol 21:1852-1858, 2010
138. Douma RA, Kok MG, Verberne LM, et al: Incidental venous thromboembolism in cancer patients: Prevalence and consequence. Thromb Res 125:e306-e309, 2010
139. Kujur R, Rao SM, Badwaik G, et al: Thrombosis associated with right internal jugular central venous catheters: A prospective observational study. Indian J Crit Care Med 16:17-21, 2012
140. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6:401-410, 2005 (Pubitemid 40753746)
141. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
142. Centers for Disease Control and Prevention: United States Cancer Statistics: 2002 Incidence and Mortality. www.cdc.gov/cancer/npcr/uscs/pdf/2002- uscs.pdf
143. Ries LAG, Eisner MP, Kossary CL, (eds): SEER Cancer Statistics Review, 1973-1997. Bethesda, MD, National Cancer Institute, 2000
144. American Cancer Society: Cancer Facts and Figures for African Americans, 2005-2006. http://www.cancer.org/acs/groups/content/@nho/documents/document/ caff2005aacorrpwsecuredpdf.pdf